Mylan launches Advair generic at 70 percent discount in US

The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said.

U.S: Mylan NV on Tuesday priced its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair 70 per cent lower than the branded medicine.

The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said.

Also Read: GSK wins new reprieve as Hikma's generic Advair delayed again

Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for the London-listed GSK.

Mylan received approval for the treatment from the U.S. Food and Drug Administration last month.

In the United States, more than 26 million people are known to have asthma, of which about seven million are children.

The FDA has declined to approve several Advair copycats including those from Novartis AG and Hikma Pharmaceuticals.

Mylan is a global generic and speciality pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA.

Also Read: FDA approves generic of Advair Diskus for asthma